Cannabidiol and Its Effects on Patients with COVID-19 Infection

Kuntzman et al., Israel Medical Association Journal, 27:2, Feb 2025
Late treatmentDouble-blind RCT · 10 patients · Israel
Cannabidiol for COVID-19
Kuntzman et al. Israel Medical Association J. · February 2025
Outcome
Improvement
Relative Risk · 95% CI
Mortality
77%0.23 · 0.01–4.49
ICU admission
57%0.43 · 0.04–4.82
Hospitalization time
22%0.78 · 0.30–2.01
00.511.52+
← Cannabidiol
reduces riskCannabidiol
increases risk →
Lower mortality with cannabidiol
Not statistically significant · p = 0.3
RCT 10 hospitalized COVID-19 patients showing potential benefit with sublingual cannabidiol (CBD) oil. There was only 7 patients in the treatment arm and 3 in the placebo group. CBD-treated patients showed a trends toward lower inflammatory cytokine levels including IL-6, IL-10, TNF-α, and C-reactive protein, though none reached statistical significance.
Important missing comments or errors? Let us know.
risk of death, 76.9% lower, RR 0.23, p = 0.30, treatment 0 of 7 (0.0%), control 1 of 3 (33.3%), NNT 3.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 57.1% lower, RR 0.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 3 (33.3%), NNT 5.2.
hospitalization time, 22.4% lower, relative time 0.78, p = 0.61, treatment mean 5.9 (±5.13) n=7, control mean 7.6 (±3.0) n=3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kuntzman et al., 28 Feb 2025, Double Blind Randomized Controlled Trial, Israel, peer-reviewed, 3 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org October 2026 Israel Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Mongolia Czechia Belarus Haiti Hong Kong Qatar Panama Serbia Israel favored high-profit treatments.The average efficacy of treatments was moderate.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org October 2026 Israel Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Czechia Belarus Qatar Panama Serbia Israel favored high-profit treatments.The average efficacy was moderate.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0